Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab + methotrexate versus methotrexate alone in methotrexate-naive psoriatic arthritis
NL-OMON44820Phase 3Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Golimumab + methotrexate with Methotrexate + placebo (2 arms). Primary endpoints: Safety up to week 22 and DAS remission up to week 22. Started Aug 2013; status: active, not recruiting.
02
Drugs
golimumabmethotrexate
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NL-OMON44820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44820.